EyeGate Pharma receives Orphan Drug Designation from FDA for treating corneal graft rejection.: An article from: Transplant News

This digital document is an article from Transplant News, published by Transplant Communications, Inc. on February 1, 2009. The length of the article is 324 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available immediately after purchase. You can view it with any web browser.

Citation Details
Title: EyeGate Pharma receives Orphan Drug Designation from FDA for treating corneal graft rejection.
Author: Gale Reference Team
Publication:Transplant News (Newsletter)
Date: February 1, 2009
Publisher: Transplant Communications, Inc.
Volume: 19 Issue: 2

Distributed by Gale, a part of Cengage Learning